SCHEMBL24223835

SCHEMBL24223835

CNc1cc(=O)[nH]c(S)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SHMT2 P34897 1/20 0.38
▸ XDH P47989 1/20 0.38
▸ NOS3 P29474 1/20 0.36
▸ NOS2 P35228 1/20 0.36
▸ NPC1 O15118 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ ABL1 P00519 1/20 0.33
▸ RIN1 Q13671 1/20 0.33
▸ MAT2A P31153 1/20 0.33
▸ CYP3A4 P08684 1/20 0.32
▸ BLM P54132 1/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ HTT P42858 1/20 0.32
▸ NUDT1 P36639 1/20 0.32
▸ HTR6 P50406 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ PKM P14618 1/20 0.31
▸ JAK1 P23458 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9543645 0.76 ABL1 (0.56) XDHABL1RIN1CYP3A4BLM
SCHEMBL19236889 0.76 SHMT2 (0.45) SHMT2XDHNOS3NOS2NPC1
SCHEMBL17422233 0.73 POLB (0.50) SHMT2XDHNOS3NOS2NPC1
Methylthiouracil SCHEMBL11433163 0.72 — —
SCHEMBL3793924 0.72 NOS3 (0.36) SHMT2XDHNOS3NOS2MAT2A
SCHEMBL17382471 0.68 — —
SCHEMBL8723531 0.68 — —
SCHEMBL25409411 0.68 KDM5B (0.38) XDHNOS3NOS2NPC1GAA
SCHEMBL6998274 0.68 LMNA (0.47) SMN1; SMN2POLBPKMTDP1
Propylthiouracil SCHEMBL4537771 0.65 BACE1 (0.64) GAASMN1; SMN2HTTKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3411411-B3 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BIOCRYST PHARM INC (US) 2022-01-26 — — EP disclosed
Send feedback